{"nctId":"NCT02720952","briefTitle":"Treatment of Adrenal Insufficiency in Children","startDateStruct":{"date":"2015-03"},"conditions":["Adrenal Insufficiency"],"count":24,"armGroups":[{"label":"Infacort","type":"EXPERIMENTAL","interventionNames":["Drug: Infacort®"]}],"interventions":[{"name":"Infacort®","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male and female children less than 6 years of age.\n2. A diagnosis of adrenal insufficiency as confirmed by an inappropriately low cortisol usually with other supporting tests.\n3. Receiving appropriate adrenocortical replacement therapy (hydrocortisone with/without fludrocortisone).\n4. Adequately hydrated and nourished.\n5. Ability of parents/carers to understand and give written Informed Consent\n\nExclusion Criteria:\n\n1. Clinically evident acute adrenal insufficiency (adrenal crisis).\n2. Inability of the child to take oral therapy.\n3. Concomitant therapy (other than that required to treat adrenal insufficiency, Vitamin D, Fluoride, Thyroxine and growth hormone).\n4. Subjects with clinical signs of acute infection or fever on Day 1.\n5. Any surgical or medical condition which in the opinion of the investigator may place the subject at higher risk from his/her participation in the study.\n6. Parents/carers of subjects unwilling to consent to saving and propagation of pseudonymised medical data for study reasons.\n7. Subjects who are dependent on the investigator or the sponsor.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Week","maximumAge":"6 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Serum Cortisol Concentration up to 240 Minutes","description":"The primary endpoint will be the maximum levels of serum cortisol concentration up to 240 minutes after intake of study drug as determined by the central laboratory.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"575.8","spread":"47.9"}]}]}]},{"type":"SECONDARY","title":"Serum Cortisol Concentration up to 6 Hours","description":"Serum cortisol concentration 240 minutes after intake of study drug as determined by the central laboratory","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.1","spread":"131.7"}]}]}]},{"type":"SECONDARY","title":"Subject Assessment of Taste of the Product","description":"Palatability of the investigational product as determined by parent/carer responses to the following questions:\n\nQuestion 1: My child found swallowing easy. Question 2: My child showed a positive reaction after Infacort was given. Question 3: I would be happy to give my child Infacort in the future. Question 4: Overall, I would prefer Infacort for my child over the usual hydrocortisone medication.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"21","spread":null},{"groupId":"OG003","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Serious Adverse Events (SAEs) and Adverse Events (AE)","description":"Incidence of serious adverse events (SAEs) and adverse events (AE).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":24},"commonTop":["Diarrhoea","Vomiting","Rash","Infantile spitting up","Hyperhidrosis"]}}}